ロード中...
THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Russo |
| 出版事項: |
Remedium Group LLC
2017-06-01
|
| シリーズ: | Медицинский совет |
| 主題: | |
| オンライン･アクセス: | https://www.med-sovet.pro/jour/article/view/1894 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|